Evidence map›Paper›PMID 33020527›Full record

ArticleScientific reports2020

Combination therapy of cold atmospheric plasma (CAP) with temozolomide in the treatment of U87MG glioblastoma cells.

Eda Gjika, Sonali Pal-Ghosh, Megan E Kirschner, Li Lin, Jonathan H Sherman, Mary Ann Stepp, Michael Keidar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 61 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Current medicinal chemistry · 2026
    Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Eda GjikaDepartment of Mechanical and Aerospace Engineering, School of Engineering and Applied Science, The George Washington University, Washington, DC, USA.
Sonali Pal-GhoshDepartment of Anatomy and Cell Biology, The George Washington University School of Medicine & Health Sciences, Washington, DC, USA.
Megan E KirschnerDepartment of Mechanical and Aerospace Engineering, School of Engineering and Applied Science, The George Washington University, Washington, DC, USA.
Li LinDepartment of Mechanical and Aerospace Engineering, School of Engineering and Applied Science, The George Washington University, Washington, DC, USA.
Jonathan H ShermanDepartment of Neurological Surgery, The George Washington University School of Medicine & Health Sciences, Washington, DC, USA.
Mary Ann SteppDepartment of Anatomy and Cell Biology, The George Washington University School of Medicine & Health Sciences, Washington, DC, USA.
Michael KeidarDepartment of Mechanical and Aerospace Engineering, School of Engineering and Applied Science, The George Washington University, Washington, DC, USA. keidar@gwu.edu.
George Washington University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cold atmospheric plasma (CAP) technology, a relatively novel technique mainly investigated as a stand-alone cancer treatment method in vivo and in vitro, is being proposed for application in conjunction with chemotherapy. In this study, we explore whether CAP, an ionized gas produced in laboratory settings and that operates at near room temperature, can enhance Temozolomide (TMZ) cytotoxicity on a glioblastoma cell line (U87MG). Temozolomide is the first line of treatment for glioblastoma, one of the most aggressive brain tumors that remains incurable despite advancements with treatment modalities. The cellular response to a single CAP treatment followed by three treatments with TMZ was monitored with a cell viability assay. According to the cell viability results, CAP treatment successfully augmented the effect of a cytotoxic TMZ dose (50 μM) and further restored the effect of a non-cytotoxic TMZ dose (10 μM). Application of CAP in conjunction TMZ increased DNA damage measured by the phosphorylation of H2AX and induced G2/M cell cycle arrest. These findings were supported by additional data indicating reduced cell migration and increased αvβ3 and αvβ5 cell surface integrin expression as a result of combined CAP-TMZ treatment. The data presented in this study serve as evidence that CAP technology can be a suitable candidate for combination therapy with existing chemotherapeutic drugs. CAP can also be investigated in future studies for sensitizing glioblastoma cells to TMZ and other drugs available in the market.

Indexed as

Antineoplastic Agents, AlkylatingApoptosisBrain NeoplasmsCell Line, TumorCell MovementCell ProliferationCell SurvivalCombined Modality TherapyDNA DamageG2 Phase Cell Cycle CheckpointsGlioblastomaHumansIntegrin alphaVbeta3M Phase Cell Cycle CheckpointsPhosphorylationPlasma GasesAntineoplastic Agents, AlkylatingIntegrin alphaVbeta3integrin alphaVbeta5Plasma GasesReceptors, VitronectinTemozolomide

Identifiers

PMID33020527
PMCPMC7536419
OpenAlexW3089828225

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.